Please assess the completion status of the following clinical trial:

Trial Title: A Study in Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes (T2D) not well controlled on 1, 2, or 3 oral antidiabetic medications~  1. Glycosylated hemoglobin (HbA1c) greater than or equal to 7 and less than or equal to 11 if taking 1 oral antidiabetic medication~ 2. HbA1c greater than or equal to 7 and less than or equal to 10 if on 2 or 3 oral antidiabetic medications~* Able to tolerate minimum dose of 1500 milligrams (mg) metformin a day and 30 mg pioglitazone per day.~* Willing to inject subcutaneous (SC) medication up to 2 times per day~* Stable weight for 3 months prior to screening~* Body mass index (BMI) between 23 and 45 kilograms per meter squared (kg/m\^2)~* Females of child bearing potential must test negative for pregnancy at screening by serum pregnancy test and be willing to use a reliable method of birth control during the study and for 1 month following the last dose of study drug.~Exclusion Criteria:~* Type 1 Diabetes~* HbA1c equal to or less than 6.5 before randomization or at randomization~* Chronic insulin use~* Taking drugs to promote weight loss by prescription or over the counter~* Taking systemic steroids for greater than 14 days except for topical, eye, nasal, or inhaled~* History of fluid retention or edema~* History of Heart Failure New York Heart Classification II, III, or IV or acute myocardial infarction or stroke within 2 months of screening~* Gastrointestinal (GI; stomach) problems such as diabetic gastroparesis or bariatric surgery (stomach stapling) or chronically taking drugs that directly affect GI motility~* Hepatitis or liver disease or alanine transaminase (ALT) greater than 2.5 times the upper limit of normal~* Acute or chronic pancreatitis of any form~* Renal disease (kidney) with a serum creatinine of greater than or equal to 1.5 milligrams per deciliter (mg/dL) for males and greater than or equal to 1.4 mg/dL for females, or a creatine clearance of less than 60 milliliters per minute (mL/min)~* History (includes family) of type 2A or 2B Multiple Endocrine Neoplasia (MEN 2A or 2B) or medullary c-cell hyperplasia or thyroid cancer~* A serum calcitonin greater than or equal to 20 picograms per milliliter (pg/mL) at screening~* Significant active autoimmune disease such as Lupus or Rheumatoid Arthritis~* History of or active malignancy except skin or in situ cervical or prostate cancer for within last 5 years~* Sickle cell, hemolytic anemia, or other hematological condition that may interfere with HbA1c testing~* Organ transplant except cornea~* Have enrolled in another clinical trial within the last 30 days~* Have previously signed an informed consent or participated in a LY2189265 (dulaglutide) study~* Have taken a glucagon-like peptide 1 (GLP-1) receptor agonist within the 3 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.5 mg LY2189265 (Type: EXPERIMENTAL): LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks
- 0.75 mg LY2189265 (Type: EXPERIMENTAL): LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks
- Exenatide (Type: ACTIVE_COMPARATOR): Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: subcutaneous (SC), once weekly for 26 weeks~LY2189265 (Dulaglutide): After 26 weeks, participants were randomized to receive either 0.75 milligrams (mg) or 1.5 mg, SC, once weekly for an additional 26 weeks (from week 26 through week 52).~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete